UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Alzheimer's & dementia, 2016-02, Vol.12 (2), p.110-120

2016

Volltextzugriff (PDF)

Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings

Current medical research and opinion, 2014-10, Vol.30 (10), p.2021-2032

2014

Volltextzugriff (PDF)

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

Alzheimer's & dementia, 2017-10, Vol.13 (10), p.1117-1124

2017

Volltextzugriff (PDF)

Function and clinical meaningfulness of treatments for mild Alzheimer's disease

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2016, Vol.2 (1), p.105-112

2016

Volltextzugriff (PDF)

Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort

Alzheimer's & dementia, 2016-09, Vol.12 (9), p.977-986

2016

Volltextzugriff (PDF)

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2019, Vol.5 (1), p.328-337

2019

Volltextzugriff (PDF)

Adverse events and dropouts in Alzheimer's disease studies: What can we learn?

Alzheimer's & dementia, 2015-01, Vol.11 (1), p.24-31

2015

Volltextzugriff (PDF)

Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies

Alzheimer's & dementia, 2012-09, Vol.8 (5), p.407-416

2012

Volltextzugriff (PDF)

Changes in Weight During a 1-Year Trial of Fluoxetine

The American journal of psychiatry, 1999-08, Vol.156 (8), p.1170-1176

1999

Volltextzugriff (PDF)

Effects of first-trimester fluoxetine exposure on the newborn

Obstetrics and gynecology (New York. 1953), 1997-05, Vol.89 (5 Pt 1), p.713-718

1997

Volltextzugriff (PDF)

Baseline characteristics of INTERCEPT‐AD: A phase 1 trial with ACU193 targeting soluble amyloid beta oligomers for the treatment of early Alzheimer’s disease

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

Topline results of INTERCEPT‐AD: A phase I trial of Aβ oligomer‐targeting ACU193 in early Alzheimer’s disease

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

Recruitment strategies and tactics for INTERCEPT‐AD: A phase I trial of Aβ oligomer‐targeting ACU193 in early Alzheimer’s disease

Alzheimer's & dementia, 2023-12, Vol.19 (S24), p.n/a

2023

Volltextzugriff (PDF)

Expression Levels of Protein Kinase C-α in Non–Small-Cell Lung Cancer

Clinical lung cancer, 2004-11, Vol.6 (3), p.184-189

2004

Volltextzugriff (PDF)

The role of protein kinase C-alpha in malignancies of the nervous system and implications for the clinical development of the specific PKC-alpha inhibitor aprinocarsen (Review)

Oncology reports, 2004-02, Vol.11 (2), p.515

2004

Volltextzugriff (PDF)

EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P605-P605

2017

Volltextzugriff (PDF)

EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P37-P38

2017

Volltextzugriff (PDF)

IC‐P‐216: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‐3 TRIAL

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_3), p.P177-P177

2018

Volltextzugriff (PDF)

O3‐13‐02: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‐3 TRIAL

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_19), p.P1055-P1056

2018

Volltextzugriff (PDF)

LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION-3 TRIAL

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P1055-P1056

2018

Volltextzugriff (PDF)

LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION-3 TRIAL

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P177-P177

2018

Volltextzugriff (PDF)

SOLANEZUMAB CENTRAL TARGET ENGAGEMENT AND PHARMACODYNAMIC ACTIVITY IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD: COMPARISON TO EXPEDITION/EXPEDITION 2

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P254-P255

2017

Volltextzugriff (PDF)

PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD

Alzheimer's & dementia, 2017-07, Vol.13 (7), p.P1452-P1452

2017

Volltextzugriff (PDF)

Changes in adverse events reported by patients during 6 months of fluoxetine therapy

The journal of clinical psychiatry, 1999-06, Vol.60 (6), p.389-394

1999

Volltextzugriff (PDF)

Birth Outcomes in Pregnant Women Taking Fluoxetine

The New England journal of medicine, 1997-03, Vol.336 (12), p.872-873

1997

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

Function and clinical meaningfulness of treatments for mild Alzheimer's disease

Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

Adverse events and dropouts in Alzheimer's disease studies: What can we learn?

Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies

Changes in Weight During a 1-Year Trial of Fluoxetine

Effects of first-trimester fluoxetine exposure on the newborn

Baseline characteristics of INTERCEPT‐AD: A phase 1 trial with ACU193 targeting soluble amyloid beta oligomers for the treatment of early Alzheimer’s disease

Topline results of INTERCEPT‐AD: A phase I trial of Aβ oligomer‐targeting ACU193 in early Alzheimer’s disease

Recruitment strategies and tactics for INTERCEPT‐AD: A phase I trial of Aβ oligomer‐targeting ACU193 in early Alzheimer’s disease

Expression Levels of Protein Kinase C-α in Non–Small-Cell Lung Cancer

The role of protein kinase C-alpha in malignancies of the nervous system and implications for the clinical development of the specific PKC-alpha inhibitor aprinocarsen (Review)

EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE

EFFECT OF SOLANEZUMAB ON BIOMARKERS OF NEURODEGENERATION IN THE EXPEDITION3 TRIAL IN MILD ALZHEIMER DISEASE

IC‐P‐216: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‐3 TRIAL

O3‐13‐02: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‐3 TRIAL

LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION-3 TRIAL

LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION-3 TRIAL

SOLANEZUMAB CENTRAL TARGET ENGAGEMENT AND PHARMACODYNAMIC ACTIVITY IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD: COMPARISON TO EXPEDITION/EXPEDITION 2

PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD

Changes in adverse events reported by patients during 6 months of fluoxetine therapy

Birth Outcomes in Pregnant Women Taking Fluoxetine

Suchergebnisse filtern